IMUX - Immunic Inc
Immunic Inc Logo

IMUX - Immunic Inc

https://imux.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.

52W High
$2.11
52W Low
$0.56
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.44
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.21
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
2.21
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
1.31%
Institutions (25–75% balanced)
53.60%
Shares Outstanding
98,651,000
Float
65,250,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-0.94
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-2.09%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0259
Previous
-0.0225
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025